Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER FINANCIAL RESULTS
Date:8/1/2013

te perception.  Activities include targeted analytical approaches to discover specific proteins that could be viable candidates for the receptors or co-factors responsible for salt taste.   The Company is currently focusing a greater effort on a smaller subset of taste bud proteins that includes potential lead candidates for the salt receptor, as well as candidates involved in signaling the sensory perception of saltiness.Intellectual Property:  Senomyx continues to be diligent in seeking protection for its intellectual property.  As of June 30, 2013, the Company is the owner or exclusive licensee of 394 issued patents and several hundred pending patent applications in the U.S., Europe, and elsewhere related to proprietary taste science technologies.Financial Review:At June 30, 2013, the Company held $37.5 million in cash, cash equivalents and investments available-for-sale.

Total revenues were $7.7 million for the quarter ended June 30, 2013, an increase from $6.9 million for the quarter ended June 30, 2012. Total revenues for the six months ended June 30, 2013 were $15.1 million compared to $15.2 million for the six months ended June 30, 2012.

Development revenues increased to $6.2 million in the second quarter of 2013 from $6.1 million in the second quarter of 2012.  Development revenues decreased to $12.2 million for the six months ended June 30, 2013 from $13.2 million for the six months ended June 30, 2012. This decrease for the six month period is primarily due to a $500,000 milestone earned in the first quarter of 2012 related to our Cooling Taste Program.  Also contributing to the decrease in development revenues for the six month period was a reduction in upfront license fee revenues recognized in 2013 compared to 2012 related to license payments under the 2009 Sweet Program collaboration with Firmenich.  There was no impact to cash flow as the license payments were received prior to 2012. 


'/>"/>
SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
2. SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
3. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
4. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
5. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
6. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
7. Visiting Nurse Association of Northern New Jersey Announces Gardening Program at Friendship House Adult Day Care
8. Metabolix Announces Second Quarter 2013 Financial Results
9. Life Technologies Announces Second Quarter 2013 Results
10. BioAstrum Announces New Transfection Tools Market Report
11. MiMedx Announces Record Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... March 30, 2015  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... No. 3:13-cv-03494-M and  Spherix v. Uniden , Case ... Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in ...
(Date:3/30/2015)... March 30, 2015  Naldemedine, an investigational peripherally ... Shionogi & Co., Ltd., met its primary and ... I) for the treatment of opioid-induced constipation (OIC) ... opioid therapy. Study results showed that naldemedine (0.2 ... the frequency of spontaneous bowel movement (SBM) compared ...
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today announced ... Molecular Intelligence®, the company,s panomic, comprehensive tumor profiling ... several rare and difficult to treat gynecological cancers ... potential to improve patient outcomes. These studies were ... Society of Gynecologic Oncology (SGO) 2015 Annual Meeting ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4
... NGSX ), a biopharmaceutical company focused on developing ... results for its fourth quarter and year-end 2007 on ... conference call to review the results will begin at ... and will be hosted by Anthony DiTonno,President and Chief ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company ... targeting the chronic inflammation,underlying cardiovascular and neurological disease, ... and Special Meeting of Shareholders,being held at the ... at 4:30 p.m. ET., To participate via ...
... Md., March 18 Martek Biosciences,(Nasdaq: MATK ) ... with,life,sDHA(TM), its patented, vegetarian form of DHA omega-3 for ... bread with vegetarian DHA,Oroweat 9 Grain Bread with life,sDHA ... in the Pacific Northwest, California, Arizona,and Nevada., "This ...
Cached Biology Technology:NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 2NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results 3Vasogen to Webcast its Annual Meeting 2Vasogen to Webcast its Annual Meeting 3Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3
(Date:3/10/2015)... March 10, 2015  Continuing its 167-year history of ... Schlemmer introduces The Eye Scanning Password Authenticator , ... access to secure websites or sensitive data. ... at international borders, the device has a small camera ... of the iris, converting them into an encrypted ID ...
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... EUREKA project E! 4104 ECOPROMAT has developed a ... protection against the spread of contagious animal diseases such ... and food production. Soaked with disinfectant solution, the matting ... shoes and boots of personnel. As it is made ...
... imitated Mother Nature by developing, for the first ... the tiny, hair-like structures through which organisms derive ... the new material isn,t exactly like cilia, it ... researchers to control it and opening unlimited possibilities ...
... the little engine that could, the University of Nevada, ... is chugging along, dwarfed by the million-gallon tanks, pipes ... where, ultimately, the plant,s electrical power could be supplied ... "We are very pleased with the results of the ...
Cached Biology News:A biological solution to animal pandemics 2A biological solution to animal pandemics 3A biological solution to animal pandemics 4Cilia revolution 2University of Nevada, Reno demonstrates successful sludge-to-power research 2University of Nevada, Reno demonstrates successful sludge-to-power research 3
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
Mouse Ameloblastin Biotinylated Affinity Purified PAb ENTREZ GeneID: 11698...
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Biology Products: